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Treatment Strategies
for Prosthetic Valve
Thrombosis–Derived
Coronary EmbolismWe recently read with great interest the report
by Lacunza-Ruiz et al. (1) describing the management
of a coronary embolism (CE) as a complication
of prosthetic mitral valve thrombosis. We thank
the authors for their report that included a
rare complication of prosthetic valve thrombosis.
However, we have some essential criticisms regarding
some major drawbacks in the management of the
patient.
CE is a rare cause of acute coronary syndrome
(ACS) in patients with prosthetic heart valves. The
majority of patients with a prosthetic heart valve
who present with ACS have non–ST-segment eleva-
tion ACS rather than ST-segment elevation ACS (2).
The information in the literature about this compli-
cation is scarce and mainly based on case reports.
There is a controversy regarding the treatment of
patients with CE. In the current literature, throm-
bolytic therapy (TT), stent implantation, and embo-
lectomy were performed as reperfusion strategies,
but there is no consensus regarding the optimal
treatment.
In the case report by Lacunza-Ruiz et al., a 66-
year-old woman with bileaﬂet mechanical mitral
prosthesis was admitted with non–ST-segment
elevation ACS. Although there was no ST-segment
elevation and the international normalized ratio
on admission was subtherapeutic, they performed
emergent coronary angiography (CAG) before eva-
luation of the prosthetic valve with transthoracic
or transesophageal echocardiography (TEE). CAG
revealed a thrombus in the middle segment of the
left anterior descending artery that was aspirated
successfully, and intracoronary ultrasound showed
an undamaged coronary wall. These ﬁndings
were consistent with a coronary embolism, so
they performed TEE, which revealed a prostheticvalve thrombosis (PVT). There is a lack of infor-
mation about what they decided to do next for
the patient. In Figure 1D, it seemed that the
thrombus burden on the prosthetic valve was
high and might include possible mobile compo-
nents, which represented a high risk of new
thromboembolisms.
First, the major concern regarding the manage-
ment of this patient is that when a patient with
prosthetic valve is admitted with non–ST-segment
elevation ACS, PVT needs to be excluded by TEE
before CAG. This strategy helps the clinician to
decide what to do during percutaneous in-
terventions. If there is no PVT, the clinician
may focus on solving only the coronary problem;
however, if there are signs of PVT, the clinician needs
to ﬁnd solutions for 2 problems. In such situations,
TT may be a favorable treatment strategy that aims to
lyse both valvular and coronary thrombi in the
absence of any contraindications. The fresh nature of
the embolic thrombus may play a role in the suc-
cessful outcome of TT. In our recently published case
series, TT was considered as an initial therapy in the
management of PVT and related CE, with successful
outcomes for both prosthetic and coronary throm-
boses (3,4).
Treatment modalities for PVT include adminis-
tering heparin, TT, and surgery. Guidelines lack
deﬁnitive class I recommendations because of the
lack of randomized, controlled trials and usually
leave the choice of treatment to the clinician’s expe-
rience. Surgery is suggested as a ﬁrst-line strategy in
most situations of left-sided PVT; however, TT was
recently used with successful outcomes (5–7). We
previously reported that a low dose (25 mg) and slow
infusion (6 h) of tissue plasminogen activator are very
safe and associated with very high thrombolytic
success in this regard (5,6). Moreover, in a recent
meta-analysis, Castilho et al. (8) reported much
higher mortality rates with surgery compared with
TT in the management of PVT (18.1% vs. 6.6%,
respectively) .
As a result, we can conclude that CAG can be
deferred until after TEE to decide the best treatment
strategy for PVT patients who present with CE. TT
should be considered as an initial treatment modality
in these patients.
Transcatheter Left Atrial
Appendage Ligation
Therapy Update
Wehave read the recent reviewby Saw andLempereur (1)
with interest because it provides a comprehensive
overview of the currently available therapies for
transcatheter left atrial appendage (LAA) closure, with
a particular emphasis on procedural imaging and
techniques (1). However, the review does not accurately
reﬂect the currently available technology with regard to
the Lariat procedure (SentreHEART, Redwood City,
California). The article repeatedly states that the Lariat
procedure is only feasible for LAA diameters <40 mm.
The Lariat Plus device has recently become available
with a snare diameter of 45 mm (compared with the
ﬁrst-generation device, which had a snare diameter of
40 mm). We have used the Lariat Plus device with
success to close an appendage >40 mm in diameter.
Other advances in this next-generation device include
improved epicardial torque control and radiopaque
markers. We thank the editors for the opportunity to
provide this important clariﬁcation related to the
rapidly evolving ﬁeld of structural heart disease.
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